Compounders Research Compare

NeuroSense Therapeutics Ltd.(NRSN)

Biotechnology · Herzliya, TA

$3.93-0.10 (-2.48%)

Delayed quote: Oct 6, 2026, 3:30 PM EDT

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

Herzliya, TA

17 employees

www.neurosense-tx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Alon Ben-Noon

View full financials

NeuroSense Therapeutics (NRSN) EV/EBITDA: History & Chart | TGMCharts

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:37:38.501Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:37:38.501Z.

Quote observation: 2026-10-06T19:34:09.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 6,946,240
Total debt · period ending 2025-12-31: 170,000
Cash · period ending 2025-12-31: 166,000
TTM operating EBITDA · period ending 2025-12-31: -11,069,000

FMP input reference: 7269c43ec051f04bc9b25698fa87f96476c1bd81d443a59abbb4ab2a9593cf8e

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NRSN EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

NRSN Competitors' EV/EBITDA Ratio

NeuroSense Therapeutics Ltd.

Current

Market Cap

$6.95M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Co-Diagnostics, Inc.

Market Cap

$6.97M

EV/EBITDA Ratio

N/A

TTM Avg

1.39x

3Y Avg

7.68x

5Y Avg

7.68x

KALA BIO, Inc.

Market Cap

$7.00M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Bolt Biotherapeutics, Inc.

Market Cap

$6.87M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Curanex Pharmaceuticals Inc Common Stock

Market Cap

$7.07M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Exicure, Inc.

Market Cap

$6.82M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Ensysce Biosciences, Inc.

Market Cap

$6.72M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Longeveron Inc.

Market Cap

$7.18M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aclarion, Inc.

Market Cap

$6.60M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Enveric Biosciences, Inc.

Market Cap

$6.65M

EV/EBITDA Ratio

N/A

TTM Avg

34.26x

3Y Avg

34.26x

5Y Avg

668.76x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
NeuroSense Therapeutics Ltd. (NRSN)	$6.95M	N/A	N/A	N/A	N/A
Co-Diagnostics, Inc. (CODX)vs ›	$6.97M	N/A	1.39x	7.68x	7.68x
KALA BIO, Inc. (KALA)vs ›	$7.00M	N/A	N/A	N/A	N/A
Bolt Biotherapeutics, Inc. (BOLT)vs ›	$6.87M	N/A	N/A	N/A	N/A
Curanex Pharmaceuticals Inc Common Stock (CURX)vs ›	$7.07M	N/A	N/A	N/A	N/A
Exicure, Inc. (XCUR)vs ›	$6.82M	N/A	N/A	N/A	N/A
Ensysce Biosciences, Inc. (ENSC)vs ›	$6.72M	N/A	N/A	N/A	N/A
Longeveron Inc. (LGVN)vs ›	$7.18M	N/A	N/A	N/A	N/A
Aclarion, Inc. (ACON)vs ›	$6.60M	N/A	N/A	N/A	N/A
Enveric Biosciences, Inc. (ENVB)vs ›	$6.65M	N/A	34.26x	34.26x	668.76x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics